Form 4: Gilead CEO Sells Shares Under Pre-Arranged 10b5-1 Plan

Gilead Sciences CEO Daniel O'Day sold a total of 10,000 shares of common stock on September 29, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Daniel Patrick O'Day, Chairman and CEO of Gilead Sciences, Inc. (GILD), reported the sale of 10,000 shares of the company's common stock.
• The transactions occurred on September 29, 2025.
• The first sale involved 8,039 shares at an average price of $111.4703 per share.
• The second sale involved 1,961 shares at an average price of $112.4193 per share.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.
• Following these reported transactions, Daniel Patrick O'Day beneficially owns 591,203 shares of Gilead Sciences common stock.

Sentiment

Score: 5

Explanation: The filing reports a pre-scheduled insider stock sale under a Rule 10b5-1 plan, which is a routine event for executives and does not inherently convey positive or negative sentiment regarding the company's immediate prospects or performance.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may note the insider sale, though its execution under a Rule 10b5-1 plan suggests it is a pre-planned diversification or liquidity event rather than a reaction to new company-specific information.

Key Dates

Recommendation

The reported insider sale by the CEO is a pre-scheduled transaction under a Rule 10b5-1 plan, adopted several months prior. Such planned sales are common for executives for diversification or liquidity purposes and do not typically signal a change in the company's fundamental outlook or warrant an immediate change in investment recommendation based solely on this filing.

Keywords

Gilead Sciences, GILD, Daniel O'Day, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Director